CD274 and neoplasm: Although there may be high levels of programmed death ligand 1 (PD-L1) expressed on both tumor and immune cells, monotherapy with anti-PD-1/PD-L1 antibodies may have limited antitumor activity and a small clinical benefit, and development of immune-oncology strategies has moved toward a combination approach with ICIs to overcome primary and acquired immune resistance [1].